Tuberculosis treatment — Competitive Intelligence Brief

Tuberculosis treatment (Tuberculosis treatment) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antitubercular. Area: Infectious Disease.

phase 3 Antitubercular InhA Infectious Disease Small molecule

Target snapshot

Tuberculosis treatment (Tuberculosis treatment) — National Institute of Allergy and Infectious Diseases (NIAID). Isoniazid works by inhibiting the synthesis of mycolic acid in Mycobacterium tuberculosis, thereby inhibiting bacterial growth and replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tuberculosis treatment TARGET	Tuberculosis treatment	National Institute of Allergy and Infectious Diseases (NIAID)	phase 3	Antitubercular	InhA
INH preventive therapy	INH preventive therapy	Johns Hopkins University	marketed	Antimycobacterial agent	InhA (enoyl-ACP reductase)
Isoniazid (Rifinah)	Isoniazid (Rifinah)	National Taiwan University Hospital	marketed	Antituberculous agent	Enoyl-ACP reductase (InhA)
Preventive treatment with Isoniazid	Preventive treatment with Isoniazid	Hospital Universitari de Bellvitge	marketed	Antimycobacterial agent	InhA (enoyl-ACP reductase); KatG (catalase-peroxidase)
Isoniazid (INH)	Isoniazid (INH)	National Institutes of Health Clinical Center (CC)	marketed	Antituberculous agent	InhA (enoyl-ACP reductase)
isoniazid and rifapentine	isoniazid and rifapentine	National Taiwan University Hospital	phase 3	Antitubercular agent	InhA (enoyl-acyl carrier protein reductase), RNA polymerase
Isoniazid with Ethambutol	Isoniazid with Ethambutol	Tuberculosis Research Centre, India	phase 3	Antituberculous agents	InhA (isoniazid); arabinosyl transferases (ethambutol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antitubercular class)

1. All India Institute of Medical Sciences · 2 drugs in this class
2. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
3. LigaChem Biosciences, Inc. · 1 drug in this class
4. Nantes University Hospital · 1 drug in this class
5. National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
6. The Aurum Institute NPC · 1 drug in this class